The company estimates $38.3M - $39.3M in Rubraca revenues for Q4 2019.
Rubraca revenues of $142M - $143M are expected for FY 2019 compared to $95.4M for FY2018.
Key milestones for 2020 include additional EU country ovarian cancer launches for Rubraca, a potential U.S. Rubraca launch in prostate cancer, initial data for lucitanib combination studies, and a planned IND filing for FAP-2286 in H2 2020.
The Company plans to release Q4 and FY 2019 financial results on February 24, 2020, after the close of the U.S. financial markets.
Shares up 1% premarket.
Try Seeking Alpha PREMIUM for unlimited analysis on CLVS